Patients with advanced NSCLC who underwent PD‐L1 testing (excluding EGFR and ALK mutations) and were treated with immunotherapy or without chemotherapy or chemotherapy alone were included. This evidence concerns the gene EGFR and non-small cell lung carcinoma.